At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
CX-4945drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Selection Phase 1 Study Evaluating the Safety and Tolerability of Silmitasertib
In Brief
A Phase 1 clinical trial evaluating CX-4945 for COVID-19. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This is a Phase I single center, open-label, parallel design in 30 subjects to evaluate safety and tolerability of CX-4945 200mg QD, 200 mg BID and 400mg BID doses (10 subjects in each regimen) for continuously 5 days in healthy subjects for dose selection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesTaiwan
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartNov 2022
Primary CompletionMar 2023
First PostedApr 2023
Study CompletionJun 2023
TodayJul 2026
First PostedApr 18, 2023
Enrollment StartNov 28, 2022
Primary CompletionMar 23, 2023
Study CompletionJun 20, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.2 years ago
Interventions
CX-4945drug
Drug: CX-4945 Silmitasertib, orally, once or twice daily for 5 days. Other Name: Silmitasertib